AIM ImmunoTech Announces Closing of its Rights Offering

Core Viewpoint - AIM ImmunoTech Inc. has successfully closed its rights offering, raising approximately $1.8 million to support the development of its lead product, Ampligen® (rintatolimod), aimed at treating late-stage pancreatic cancer, a significant global health issue [1][5]. Group 1: Rights Offering Details - The rights offering allowed holders to purchase one unit at a subscription price of $1,000, which included one share of Series G Convertible Preferred Stock and 2,000 Class G Common Stock Purchase Warrants [2]. - Maxim Group LLC served as the dealer-manager for the rights offering [2]. Group 2: Regulatory Information - The registration statement for the rights offering was declared effective by the SEC on February 10, 2026, with modifications made in a prospectus supplement filed on February 27, 2026 [3]. - The prospectus detailing the terms of the rights offering is available on the SEC's website [3]. Group 3: Company Overview - AIM ImmunoTech Inc. focuses on the research and development of Ampligen®, which is a dsRNA and selective TLR3 agonist immuno-modulator showing broad-spectrum activity in clinical trials for late-stage pancreatic cancer [5].